Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,910 matching trials from the local directory fallback.

Filters: Baltimore, Maryland Clear all

Conditions: Alcohol Use Disorder, Substance Use Disorder
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2047
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mesial Temporal Lobe Epilepsy
Interventions: AAV9-hSyn1-miGRIK2; Genetic
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more

Conditions: Anxiety, Opioid Craving, Opioid Use Disorder, Opioid Withdrawal
Interventions: Buspirone, Lofexidine, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infection, Liver Transplant
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Cardiovascular Disease
Interventions: Olpasiran, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years to 105 Years
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 205
States / cities: Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more

Conditions: Chronic Low Back Pain
Interventions: In-Clinic Physical Therapy, Telehealth Physical Therapy (Telerehabilitation); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • Salt Lake City, Utah

Conditions: HER2-negative Breast Cancer Patients With Brain Metastases
Interventions: Utidelone, Utidelone in combination with capecitabine; Drug
Lead sponsor: Biostar Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 9 more

Conditions: Adrenal Insufficiency, Arrythmia, Asthma in Children, Attention Deficit Hyperactivity Disorder, Bronchopulmonary Dysplasia, Coagulation Disorder, Coronavirus Infection (COVID-19), Down Syndrome, Edema, Fibrinolysis; Hemorrhage, Heart Failure, Hemophilia, Hyperphosphatemia, Hypertension, Hypokalemia, Insomnia, Kawasaki Disease, Menorrhagia, Multisystem Inflammatory Syndrome in Children (MIS-C), Pain, Pneumonia, Primary Hyperaldosteronism, Pulmonary Arterial Hypertension, Skin Infection, Urinary Tract Infections in Children
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Amyotrophic Lateral Sclerosis, Brainstem Stroke, Locked-in Syndrome, Tetraplegia
Interventions: Surgical implantation of CortiCom system; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Quadriplegia, Tetraplegia
Interventions: BiCNS; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tracheal Stenosis
Interventions: Bronchoscopy, carbon dioxide (CO2) laser wedge resection, Radial incision with dilation; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Muscle Invasive Bladder Cancer
Interventions: Docetaxel, Gemcitabine, Nadofaragene Firadenovec; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions: Pocenbrodib, Pocenbrodib and Darolutamide; Drug
Lead sponsor: Pathos AI, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 19
States / cities: Fountain Valley, California • Los Alamitos, California • Aurora, Colorado + 16 more

Conditions: Cardiac Sarcoidosis
Interventions: Rilonacept; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Rochester, Minnesota

Conditions: Adolescent, Substance Abuse, Substance Use, Suicide
Interventions: Control, Peer Support Services (PSS), WisePath for Teens; Device · Behavioral · Other
Lead sponsor: Evidence-Based Practice Institute, Seattle, WA; Industry
Eligibility: 13 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: Transcranial Magnetic Stimulation (TMS); Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 45
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 37 more

Conditions: Cancer, Myocarditis Acute
Interventions: Abatacept plus, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 29
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more

Conditions: Cystic Fibrosis, Infections
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: Bone Cancer Metastatic
Interventions: Percutaneous Ablation, Radiation Therapy; Device · Radiation
Lead sponsor: Society of Interventional Oncology; Other
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Miami, Florida • Atlanta, Georgia + 4 more

Conditions: Aneurysm Dissecting, Aneurysm Thoracic, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta, Intramural Hematoma, Transection Aorta, Vascular Disease
Interventions: Endovascular; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 24
States / cities: Tucson, Arizona • Los Angeles, California • Stanford, California + 19 more

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: Mavacamten, Non-mavacamten symptomatic oHCM therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 60
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more

Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Endometrial Cancer, Lymphoma, T-Cell, Mesothelioma, Malignant, Metastatic Castration-resistant Prostate Cancer, Ovarian Clear Cell Carcinoma, Prostatic Neoplasms, Castration-Resistant
Interventions: Enzalutamide, Tulmimetostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 22
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Smoldering Plasma Cell Myeloma
Interventions: Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Biological · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 742
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 490 more

Conditions: Heart Failure, Obesity
Interventions: NNC0487-0111, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 5,610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 206
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more

Search by objective public record fields.

Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Evaluating Buspirone to Treat Opioid Withdrawal

Expanding HOPE Liver

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Telerehabilitation for Patients With Chronic Low Back Pain (TeleBACK Clinical Trial)

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Investigation on the Cortical Communication (CortiCom) System

Investigation on the Bidirectional Cortical Neuroprosthetic System

Transcriptomic Profile Changes in Benign Tracheal Stenosis: Wedge Resection vs. Radial Incision

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Rilonacept in Subjects With Cardiac Sarcoidosis

Mobile Technology to Reduce Teen Substance Misuse

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Remote Sputum Collection in Cystic Fibrosis

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity